(Q37772888)

22 August 2017

1 reference

title

Role of CXCR4 in HIV infection and its potential as a therapeutic target (English)

1 reference

22 August 2017

Tsutomu Murakami

1

1 reference

22 August 2017

Naoki Yamamoto

series ordinal

2

1 reference

22 August 2017

publication date

1 July 2010

1 reference

22 August 2017

number of pages

15

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

22 August 2017

volume

5

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

1025-1039

1 reference

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

22 August 2017

cites work

1 reference

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

21 January 2018

1 reference

Etravirine for the treatment of HIV infection.

21 January 2018

1 reference

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis

21 January 2018

1 reference

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

21 January 2018

1 reference

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

21 January 2018

1 reference

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

21 January 2018

1 reference

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

21 January 2018

1 reference

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

21 January 2018

1 reference

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

21 January 2018

1 reference

Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1

21 January 2018

1 reference

The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection

21 January 2018

1 reference

The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop

21 January 2018

1 reference

HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors

21 January 2018

1 reference

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

21 January 2018

1 reference

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SF

21 January 2018

1 reference

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

21 January 2018

1 reference

The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression

21 January 2018

1 reference

Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression

21 January 2018

1 reference

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

21 January 2018

1 reference

The bicyclam AMD3100 story

21 January 2018

1 reference

Recent patents regarding the discovery of small molecule CXCR4 antagonists

21 January 2018

1 reference

Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity

21 January 2018

1 reference

A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)

21 January 2018

1 reference

Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion

21 January 2018

1 reference

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection

21 January 2018

1 reference

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor

21 January 2018

1 reference

A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

21 January 2018

1 reference

Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes

21 January 2018

1 reference

Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries

21 January 2018

1 reference

Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

21 January 2018

1 reference

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

21 January 2018

1 reference

The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.

21 January 2018

1 reference

Safe use of the CXCR4 inhibitor ALX40-4C in humans

21 January 2018

1 reference

Anti-HIV activity of a novel aminoglycoside-arginine conjugate

21 January 2018

1 reference

Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection

21 January 2018

1 reference

Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.

21 January 2018

1 reference

Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles

21 January 2018

1 reference

Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor

21 January 2018

1 reference

Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry

21 January 2018

1 reference

Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor

21 January 2018

1 reference

Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists

21 January 2018

1 reference

Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site

21 January 2018

1 reference

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans

21 January 2018

1 reference

Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist

21 January 2018

1 reference

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

21 January 2018

1 reference

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha

21 January 2018

1 reference

Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.

21 January 2018

1 reference

Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.

21 January 2018

1 reference

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

21 January 2018

1 reference

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

21 January 2018

1 reference

Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss

21 January 2018

1 reference

Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry

21 January 2018

1 reference

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

21 January 2018

1 reference

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

21 January 2018

1 reference

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

21 January 2018

1 reference

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors

21 January 2018

1 reference

Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

21 January 2018

1 reference

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

21 January 2018

1 reference

Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

21 January 2018

1 reference

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

21 January 2018

1 reference

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject

21 January 2018

1 reference

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.

21 January 2018

1 reference

Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin

21 January 2018

1 reference

Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer.

21 January 2018

1 reference

Cancer and the chemokine network

21 January 2018

1 reference

Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis

21 January 2018

1 reference

CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.

21 January 2018

1 reference

Involvement of chemokine receptors in breast cancer metastasis

21 January 2018

1 reference

Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases

21 January 2018

1 reference

Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside

21 January 2018

1 reference

Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.

21 January 2018

1 reference

CXCR4 regulates growth of both primary and metastatic breast cancer

21 January 2018

1 reference

Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists

21 January 2018

1 reference

CXCR4 is a major chemokine receptor on glioma cells and mediates their survival

21 January 2018

1 reference

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

21 January 2018

1 reference

The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis

21 January 2018

1 reference

SDF1 gene variation is associated with circulating SDF1alpha level and endothelial progenitor cell number: the Bruneck Study

21 January 2018

1 reference

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma

21 January 2018

1 reference

Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs

21 January 2018

1 reference

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

21 January 2018

1 reference

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity

21 January 2018

1 reference

Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1

21 January 2018

1 reference

The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract

21 January 2018

1 reference

Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development

21 January 2018

1 reference

Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FMB.10.67

1 reference

22 August 2017

1 reference